Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. - Wikidata - awgldk - TriplyDB

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

http://www.wikidata.org/entity/Q33343262

about

Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.Prevention of hepatitis B virus reactivation under rituximab therapy.Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.Reactivation of hepatitis B virus with rituximab.Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.Treatment of follicular lymphoma: current status.Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.Rituximab therapy in nephrotic syndrome: implications for patients' management.Rituximab biosimilars.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Optimizing drug development in oncology by clinical trial simulation: Why and how?Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.Rituximab and other emerging monoclonal antibody therapies for lymphoma.Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.

P2860

Q33369667-F731BB9E-0271-4446-A263-922C4474965A Q33388543-A9751C90-8DF5-431E-B1AE-B8B3B536A8A9 Q33390799-84DF26CE-4AAC-4DC7-BCAB-9C523DA67AE5 Q33695997-04907F31-CD0B-4636-B0A7-BDEF4BC00A14 Q34065271-D0B76797-B5A2-4F84-9B1D-A06E6B0126AC Q34272887-AD69EB90-D4BD-4F69-B711-FB357A2996BB Q36036378-8DFBFA15-0F5C-42E2-BA47-7604DA8F89CB Q36150595-C7A82731-91B7-4D14-8F01-E57290998BF1 Q36216264-AF9EE0C1-D04C-4642-ACA7-6AD75C2F1F4A Q36584818-F54DE53A-5E3F-4635-ACD6-E5E9C182503A Q36897238-3B711417-121B-4452-931D-51081E514781 Q37079029-EDCA8561-DC02-4A2A-B498-D570C3EBF85C Q37280915-7B4F34AA-5608-4B35-930E-C277AF4BB947 Q37530222-A558C284-0EA0-42EE-83AE-31057E3D850D Q38075787-54E2E8DD-A92F-4B57-86AC-0AAEC2910CA2 Q38100232-2D02016C-8CB3-4D7F-AC24-C146AFF0E6B2 Q38530254-BE7E211C-517C-4F71-97D0-89FA0BEEBA89 Q38564877-EEEB0842-EC31-4FD3-ADDA-826D1B028C19 Q38675644-068B06D9-ED44-4C48-B2D9-F50953AF650E Q39937143-6746ACDB-DBFA-4E8D-8E9F-42DBC1B8D843 Q40409351-685B3217-56D4-4ECA-AE31-BB8B93CEE5C5 Q40533983-1E30F3E4-0CCC-4DDC-A2E6-C0DD5FE58A0F Q46675870-70DF352D-CA58-457D-9BB9-F74F915D2373 Q51028994-49C85CFC-ED48-423E-9480-E0EF3B0F1D75 Q51749848-70438AF8-A061-4994-9CA8-74BB83A3B0E8 Q53278107-DFA19F0A-A93B-4190-A9C3-E9B8E6DB9E51

P2860

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

http://www.wikidata.org/entity/Q33343262

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Factors affecting toxicity, re ...... ab: a Japanese phase II study.

@ast

Factors affecting toxicity, re ...... ab: a Japanese phase II study.

@en

type

label

Factors affecting toxicity, re ...... ab: a Japanese phase II study.

@ast

Factors affecting toxicity, re ...... ab: a Japanese phase II study.

@en

prefLabel

Factors affecting toxicity, re ...... ab: a Japanese phase II study.

@ast

Factors affecting toxicity, re ...... ab: a Japanese phase II study.

@en

P1433

Q33343262-272B1066-8299-489D-8E1D-CD07EF18EC2D

P1476

Q33343262-D9971AF9-6868-4F60-9523-D8B011EC3519

P2093

Q33343262-4895F25B-CA94-4EF1-A20C-5A2BD8AE438B

Q33343262-57CAE355-DC28-4ECF-8FA8-396FEDBD179E

Q33343262-5899EEF9-CE4C-4CB9-A28A-7E58783FF617

Q33343262-600C78A8-B1EB-41CF-952C-791C09A65B1F

Q33343262-70EC6E4F-D772-425B-BB21-AF06C711DE81

Q33343262-7467CFB4-929D-44D1-ABB1-705824D481A2

Q33343262-B16B1A64-BE7F-40DC-B99C-2D927BF738CA

Q33343262-B483C820-63A1-44AD-BFC6-650E8877696C

Q33343262-B51D7EEB-FD9F-4140-A20A-5D1972C88AC5

Q33343262-CF632472-2AD8-4042-86C7-F97F4F8DDD76

P2860

Q33343262-036E06C2-98CD-43D7-8021-BD7F600B9E82

Q33343262-064AB96C-8D6D-435C-AC6D-359B66293A1C

Q33343262-17AB72E9-80E7-48A5-98D7-B9A09BFAFF6A

Q33343262-2AC19474-96EE-4A2B-A05A-2BB2928011C2

Q33343262-38B1066C-3EE1-4D02-AB31-049B20BD9F18

Q33343262-480D8A72-C5F8-44D0-B2FA-0D2DEFFB8CBA

Q33343262-4B8477EF-4107-4214-9335-444E2E53F77F

Q33343262-614D9068-3E58-4A6D-8159-409ED9CF6501

Q33343262-76A75B5B-6661-4F52-8421-AB3D5C1335EC

Q33343262-77629686-292D-4032-8A5B-C5B90D3279D5

P304

Q33343262-4AF5689C-12F5-4477-A858-CD1EE1D04C33

P31

Q33343262-5F87833D-9E0C-4B9B-BBEC-B769A3F0079E

P356

Q33343262-A7196BDE-6288-43D7-A2A2-7E79B6404319

P433

Q33343262-1FF509D0-5557-4A7C-8A30-CD53F06B258C

P478

Q33343262-C780E3D6-961D-4969-AFBB-F1D2BA40B071

P50

Q33343262-B6696B19-52F2-49E6-9ED6-9624C6B36AD5

P577

Q33343262-36A0A2A5-5DE6-4FF2-B703-75D3C3718140

P5875

Q33343262-654852A6-6895-426D-9415-BAC51874A67F

P698

Q33343262-EC3B30E9-5A12-4721-8EAD-52A49AC2DDBE

P356

P1433

Annals of Oncology

P1476

Factors affecting toxicity, re ...... ab: a Japanese phase II study.

@en

P2093

IDEC-C2B8 Study Group in Japan

http://www.w3.org/2001/XMLSchema#string

K Ohnishi

http://www.w3.org/2001/XMLSchema#string

K Tobinai

http://www.w3.org/2001/XMLSchema#string

M Kasai

http://www.w3.org/2001/XMLSchema#string

M Ogura

http://www.w3.org/2001/XMLSchema#string

M Taniwaki

http://www.w3.org/2001/XMLSchema#string

N Uike

http://www.w3.org/2001/XMLSchema#string

S Mori

http://www.w3.org/2001/XMLSchema#string

S Nakamura

http://www.w3.org/2001/XMLSchema#string

T Igarashi

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.

Phase I study of the combination of monthly carboplatin and weekly cisplatin.

Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas.

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan.

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.

Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.

P304

928-943

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDF155

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Yukio Kobayashi

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11256341

http://www.w3.org/2001/XMLSchema#string

P698

12123339

http://www.w3.org/2001/XMLSchema#string